Author

Yoonyeong Lee

Institution: SK bioscience Co., Ltd. (South Korea)

Observed institutions: Seoul National University, SK bioscience Co., Ltd. (South Korea)

ORCID: 0000-0002-1587-4961

Observed ORCID: 0000-0002-1587-4961

OpenAlex ID: A5011698085

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

2021 · Ganesh Kumar Rai, Tarun Saluja, et al. · The Lancet Infectious Diseases · 37

Cyclic Bis-1,3-dialkylpyridiniums from the Sponge Haliclona sp.

2012 · Yoonyeong Lee, Kyoung Hwa Jang, et al. · Marine Drugs · 32

Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study

2020 · Maria Rosario Capeding, Arijit Sil, et al. · EClinicalMedicine · 24

Bioactive lipids from the sponge Spirastrella abata

2011 · Kyoung Hwa Jang, Yoonyeong Lee, et al. · Bioorganic & Medicinal Chemistry Letters · 14

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

2022 · Maria Rosario Capeding, Birkneh Tilahun Tadesse, et al. · npj Vaccines · 12

Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infants

2022 · Tarun Saluja, Ganesh Kumar Rai, et al. · Vaccine · 10

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age

2022 · Josefina Cadorna Carlos, Birkneh Tilahun Tadesse, et al. · The Lancet Regional Health - Western Pacific · 3

Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial

2026 · Yoonsun Yoon, Hye-Kyung Cho, et al. · Vaccines · 1

Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trial

2025 · Joon Young Song, Won Suk Choi, et al. · International Journal of Infectious Diseases · 1

ChemInform Abstract: Bioactive Lipids from the Sponge Spirastrella abata.

2012 · Kyoung Hwa Jang, Yoonyeong Lee, et al. · ChemInform

Works count: 10

Citation count: 134

H-index: 6

I10-index: 6